Effect of propentofylline and pentoxifylline on cerebral blood flow using 123I-IMP SPECT in patients with cerebral arteriosclerosis. 1994

R Torigoe, and T Hayashi, and S Anegawa, and K Harada, and K Toda, and K Maeda, and M Katsuragi
Department of Neurosurgery, Institute of Neurosciences, Kurume-shi, Japan.

Propentofylline and pentoxifylline were administered to patients age 65 years or older who were suffering from chronic cerebrocirculatory insufficiency. Changes in clinical symptoms and the level of cerebral blood flow before and after drug administration were compared. 123I-IMP single photon emission computed tomography was used to compare cerebral blood flow before treatment with that 3 months after initiation of therapy. Focal regions of interest were established in the cerebellum, the frontal, temporal, parietal, and occipital lobes, and the thalamus. Comparisons were made between patients age 75 years or older (very old age group) (n = 5) and those age 65 to 74 years (old age group) (n = 7). Complaints of dizziness and slight headache disappeared by the eighth week after the start of therapy in both age groups. Two of the five patients in the very old age group showed elimination of memory disturbance symptoms at the 12th week of treatment. Six of the seven patients in the old age group had no memory disturbance symptoms by the eighth week of treatment, which indicates a high therapeutic effect in this group. In the cerebral blood flow studies, no increases in blood flow after drug administration were observed in the very old age group. This finding is probably related to the poor level of recovery achieved in disturbances in memory in this group. In contrast, improvements in blood flow were observed for all regions of the brain monitored in the old age group, which is consistent with the amelioration of clinical symptoms observed in these patients.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D010431 Pentoxifylline A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. Agapurin,BL-191,Oxpentifylline,Pentoxil,Torental,Trental,BL 191,BL191
D002537 Intracranial Arteriosclerosis Vascular diseases characterized by thickening and hardening of the walls of ARTERIES inside the SKULL. There are three subtypes: (1) atherosclerosis with fatty deposits in the ARTERIAL INTIMA; (2) Monckeberg's sclerosis with calcium deposits in the media and (3) arteriolosclerosis involving the small caliber arteries. Clinical signs include HEADACHE; CONFUSION; transient blindness (AMAUROSIS FUGAX); speech impairment; and HEMIPARESIS. Cerebral Arteriosclerosis,Intracranial Atherosclerosis,Cerebral Atherosclerosis,Arterioscleroses, Cerebral,Arterioscleroses, Intracranial,Arteriosclerosis, Cerebral,Arteriosclerosis, Intracranial,Atheroscleroses, Cerebral,Atheroscleroses, Intracranial,Atherosclerosis, Cerebral,Atherosclerosis, Intracranial,Cerebral Arterioscleroses,Cerebral Atheroscleroses,Intracranial Arterioscleroses,Intracranial Atheroscleroses
D002560 Cerebrovascular Circulation The circulation of blood through the BLOOD VESSELS of the BRAIN. Brain Blood Flow,Regional Cerebral Blood Flow,Cerebral Blood Flow,Cerebral Circulation,Cerebral Perfusion Pressure,Circulation, Cerebrovascular,Blood Flow, Brain,Blood Flow, Cerebral,Brain Blood Flows,Cerebral Blood Flows,Cerebral Circulations,Cerebral Perfusion Pressures,Circulation, Cerebral,Flow, Brain Blood,Flow, Cerebral Blood,Perfusion Pressure, Cerebral,Pressure, Cerebral Perfusion
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014970 Xanthines Purine bases found in body tissues and fluids and in some plants.
D015899 Tomography, Emission-Computed, Single-Photon A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image. CAT Scan, Single-Photon Emission,CT Scan, Single-Photon Emission,Radionuclide Tomography, Single-Photon Emission-Computed,SPECT,Single-Photon Emission-Computed Tomography,Tomography, Single-Photon, Emission-Computed,Single-Photon Emission CT Scan,Single-Photon Emission Computer-Assisted Tomography,Single-Photon Emission Computerized Tomography,CAT Scan, Single Photon Emission,CT Scan, Single Photon Emission,Emission-Computed Tomography, Single-Photon,Radionuclide Tomography, Single Photon Emission Computed,Single Photon Emission CT Scan,Single Photon Emission Computed Tomography,Single Photon Emission Computer Assisted Tomography,Single Photon Emission Computerized Tomography,Tomography, Single-Photon Emission-Computed

Related Publications

R Torigoe, and T Hayashi, and S Anegawa, and K Harada, and K Toda, and K Maeda, and M Katsuragi
May 1987, Neurologia medico-chirurgica,
R Torigoe, and T Hayashi, and S Anegawa, and K Harada, and K Toda, and K Maeda, and M Katsuragi
May 1988, No to hattatsu = Brain and development,
R Torigoe, and T Hayashi, and S Anegawa, and K Harada, and K Toda, and K Maeda, and M Katsuragi
July 1991, Nihon rinsho. Japanese journal of clinical medicine,
R Torigoe, and T Hayashi, and S Anegawa, and K Harada, and K Toda, and K Maeda, and M Katsuragi
August 1986, Neurologia medico-chirurgica,
R Torigoe, and T Hayashi, and S Anegawa, and K Harada, and K Toda, and K Maeda, and M Katsuragi
July 1993, Kaku igaku. The Japanese journal of nuclear medicine,
R Torigoe, and T Hayashi, and S Anegawa, and K Harada, and K Toda, and K Maeda, and M Katsuragi
June 1994, Nuclear medicine communications,
R Torigoe, and T Hayashi, and S Anegawa, and K Harada, and K Toda, and K Maeda, and M Katsuragi
January 1996, Kaku igaku. The Japanese journal of nuclear medicine,
R Torigoe, and T Hayashi, and S Anegawa, and K Harada, and K Toda, and K Maeda, and M Katsuragi
August 2003, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi,
R Torigoe, and T Hayashi, and S Anegawa, and K Harada, and K Toda, and K Maeda, and M Katsuragi
March 1993, Kaku igaku. The Japanese journal of nuclear medicine,
R Torigoe, and T Hayashi, and S Anegawa, and K Harada, and K Toda, and K Maeda, and M Katsuragi
March 1996, Kaku igaku. The Japanese journal of nuclear medicine,
Copied contents to your clipboard!